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 Introduction 
 Uveal melanoma is the most common primary malig-
nant intraocular tumor in adults. The 5-, 10- and 15-year 
survival rates based on tumor-related mortality are re-
ported to be 72, 59 and 53%, respectively. Uveal melano-
ma typically metastasizes to the liver. Following the diag-
nosis of metastatic disease, the median time of survival 
decreases to less than 1 year  [1, 2] . An appropriate screen-
ing for early detection of metastatic disease is essential in 
order to lower melanoma-related mortality  [3] .
 The Collaborative Ocular Melanoma Study Group 
(COMS) recommends a semiannual evaluation of liver 
function tests as screening tool for metastatic disease  [4] . 
In case of suspected metastatic disease abdominal ultra-
sonography is recommended as an initial examination in 
addition to chest radiography to rule out metastases from 
lung cancer to the eye  [1, 5] . Besides these examinations, 
a sensitive and specific serological marker for the early 
detection of metastatic disease would be of great value.
 Two promising proteins have recently been reported, 
namely ‘melanoma inhibitory activity’ (MIA)  [6–8] and 
osteopontin (OPN)  [9, 10] . The latter is expressed by var-
ious cell types and its expression has been shown to en-
hance tumorigenicity and metastases  [11] , to lead to more 
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 Abstract 
 Background: Evaluation of the protein osteopontin (OPN)
as a potential new marker in comparison to melanoma in-
hibitory activity (MIA) for screening and detection of meta-
static uveal melanoma.  Methods: Plasma levels of 32 pa-
tients with uveal melanoma were analyzed for OPN and MIA 
by enzyme-linked immunosorbent assay (ELISA). Fourteen 
of these patients had clinically detectable liver metastases. 
 Results: Median plasma concentration of OPN in patients 
with metastatic disease was 152.01 ng/ml compared to 47.39 
ng/ml in patients without clinically detectable metastases 
(p  ! 0.001). The difference between the median MIA plasma 
levels in patients with (13.11 ng/ml) and patients without 
(5.64 ng/ml) metastatic disease was also statistically signifi-
cant (p  ! 0.001). No correlation could be found between MIA 
or OPN levels and tumor height in patients without clinically 
detectable metastases.  Conclusion: The proteins MIA and 
OPN seem to be promising tumor markers for the metastasis 
screening in patients with uveal melanoma. 
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aggressive tumor growth in various cancers  [12] and to 
increase the invasive behavior of cutaneous melanoma 
cells  [13] .
 This study was designed to compare OPN and MIA 
plasma levels in patients with uveal melanoma both with 
and without metastatic disease, and to evaluate the im-
pact of tumor size on plasma levels of both proteins.
 Materials and Methods 
 Thirty-three plasma samples of 32 patients with uveal mela-
noma were analyzed. OPN and MIA plasma levels were quanti-
fied by an enzyme-linked immunosorbent assay (ELISA). Four-
teen of these patients had clinically proven metastases. In 1 of the 
14 patients with metastatic disease two samples were available, 
one taken before and one after the development of clinically de-
tectable metastases. Screening for metastatic disease was done by 
a tumor specialist by using liver ultrasound and liver enzymes 
(alkaline phosphates, AST, ALT and bilirubin) as well as chest X-
ray. Abnormal findings triggered the administration of a subse-
quent diagnostic test such as computed tomography (CT) scan, 
magnetic resonance imaging (MRI) or biopsy.
 Sample collection was performed after written informed con-
sent had been obtained. The study followed the principles ex-
pressed in the Declaration of Helsinki and had been approved by 
the local ethics committee. Data of these 32 patients were already 
partly used in previous studies  [10] .
 Tumor height was measured by standardized echography us-
ing A-scan techniques described previously  [14] at the time when 
blood samples were obtained from the patients. According to the 
tumor height measured, patients without clinically detectable 
metastases were divided into the following three groups: small 
melanomas ( 6 3 mm), medium-sized melanomas (3–5 mm) and 
large melanomas ( 6 5 mm).
 Plasma levels of OPN and MIA were both evaluated with an 
ELISA test kit (R&D Systems, Minneapolis, Minn., USA and 
Roche, Mannheim, Germany, respectively) according to the man-
ufacturer’s instructions. The reliability and reproducibility of 
both kits have previously been described in the literature  [9, 15] . 
The blood samples for the examinations of both markers were 
drawn from the same patients. Statistical analysis was performed 
using the Mann-Whitney U test, Wilcoxon test and Kruskal-Wal-
lis test. Data were collected and analyzed using Microsoft Excel 
and SPSS 11.0 for Windows.
 Results 
 Seventeen (53%) of the 32 patients were female and 15 
(47%) patients were male. Patients’ age varied from 37 to 
81 years (median 58 years). Patients without clinically de-
tectable metastases had a median apical tumor height of 
5.0 mm. Six patients had small melanomas ( ^  3 mm), 4 
patients had medium-sized melanomas (3–5 mm) and 8 
patients had large melanomas ( 6 5 mm) ( table 1 ). The 
median apical tumor height in patients with clinically de-
tectable metastases was 6.5 mm.
 Concerning therapy for the primary tumor in the 
group of patients without metastases, 15 of 18 patients 
had already been treated: 7 by  106 Ru plaque brachythera-
py, 7 by irradiation using the gamma knife and 1 patient 
by enucleation. In the group of patients with metastatic 
disease, 12 of 14 patients had been treated for primary 
tumor: 5 were irradiated with the gamma knife and 1 
with proton beam, 3 were treated with  106 Ru plaque 
brachytherapy, 2 patients received transpupillary ther-
motherapy (1 of them was later on enucleated because of 
tumor recurrence) and another patient was primarily 
enucleated.
 The median plasma concentration of OPN in patients 
without clinically detectable metastases was 47.39 ng/ml 
(25th percentile: 37.69 ng/ml; 75th percentile: 75.49 ng/
ml) ( table 2 ). There was no statistically significant differ-
ence between plasma levels in patients with small, me-
dium-sized or large melanoma in this study population 
(p  1 0.2, Kruskal-Wallis test) ( table 1 ). The median OPN 
level in patients with metastatic uveal melanoma was 
152.01 ng/ml (25th percentile: 87.52 ng/ml; 75th percen-
tile: 233.45 ng/ml). The difference between patients with 
and without clinically detectable metastases was statisti-
cally highly significant (p  ! 0.001, Mann-Whitney U test) 
( fig. 1 ,  table 2 ).
 The median MIA level in patients without metastatic 
disease was 5.64 ng/ml (25th percentile: 4.63 ng/ml; 75th 
percentile: 8.0 ng/ml) ( table 2 ). As for OPN, no correla-
tion could be found between MIA level and tumor height 
in this group (p  1 0.7, Kruskal-Wallis test) ( table 1 ). The 
median MIA level for patients with metastatic disease 
was 13.11 ng/ml (25th percentile: 8.89 ng/ml; 75th per-
centile: 37.05 ng/ml). As for OPN, the difference between 
the MIA levels in patients with and without clinically de-
tectable metastases was statistically significant (p  ! 0.001, 
Mann-Whitney U test) ( fig. 1 b,  table 2 ).
 In the patient with metastatic disease, in whom the 
levels of OPN and MIA could be measured before and 
after the development of metastases, the concentrations 
of OPN and MIA were 118.67 and 9.8 ng/ml before and 
375.54 and 26.53 ng/ml after generalization, respectively 
(p  ! 0.001, Wilcoxon test).
 In general, a comparison between OPN or MIA plas-
ma levels and tumor burden or stage of metastases was 
very difficult, because all 14 patients had diffuse liver me-
tastases. The median time gap between diagnosis of me-
tastases and sample collection was 3 months.
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 Discussion 
 There are several established parameters to identify 
patients at high risk of metastatic disease such as histo-
logical cell type, largest tumor diameter, tumor location 
and specific microcirculation patterns  [2, 16] . All these 
predictors of metastatic disease may help to indicate the 
risk of developing metastatic disease; they are, however, 
not able to detect metastatic disease itself.
 The protein MIA, an attachment regulating protein, 
was already described as a tumor marker for cutaneous 
melanomas  [15] . MIA specifically inhibits the attach-
ment of melanoma cells to fibronectin and laminin and 
is therefore presumed to influence the detachment of 
melanoma cells from extracellular matrix. Therefore, 
MIA is considered to play an important role in the patho-
genesis of metastases.
 As in earlier studies  [6–8] we were again able to dem-
onstrate that elevated MIA plasma levels indicate meta-
static disease also in the malignant melanoma of the uvea. 
These results have recently been confirmed by Barak et 
al.  [17] .
 OPN is a 314-amino acid phosphoglycoprotein that is 
a component of the noncollagenous bone matrix. OPN 
has been described in the context of diverse physiological 
roles such as chemotaxis, cell migration and adhesion, 
angiogenesis, apoptosis, cell-extracellular matrix inter-
actions and immune regulation  [18] . OPN actively pro-
motes the tumorigenic phenotype and contributes to me-
tastases. Increased OPN expression is associated with ag-
gressive behavior and metastases in breast, colon, prostate, 
lung, liver and ovarian cancers  [11] . OPN is secreted into 
the blood where it can be detected by ELISA. Elevated 
plasma levels have been observed in patients with ad-
vanced or metastatic cancers, including cutaneous mela-
Table 1. No statistically significant difference between plasma 
levels in patients with small, medium-sized or large melanomas 
could be seen for OPN and MIA in the group without clinically 
detectable metastases
Apical tumor thickness p
≤3 mm
(n = 6)
3–5 mm
(n = 4)
≥5 mm
(n = 8)
OPN median, ng/ml 43.22 44.59 60.13 >0.2
25th percentile 26.65 42.36 40.85
75th percentile 65.08 54.28 84.59
MIA median, ng/ml 6.31 6.49 5.16 >0.7
25th percentile 4.84 3.25 4.28
75th percentile 7.82 8.37 6.69
Table 2. OPN and MIA plasma levels in patients with and without 
clinically detectable metastases; the difference between these 
groups was statistically highly significant (Mann-Whitney U 
test)
Metastases p
no yes
OPN median, ng/ml 47.39 152.01 <0.001
25th percentile 37.69 87.52
75th percentile 75.49 233.45
MIA median, ng/ml 5.64 13.11 <0.001
25th percentile 4.63 8.89
75th percentile 8.0 37.05
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 Fig. 1. OPN ( a ) and MIA ( b ) plasma levels 
in patients with and without clinically de-
tectable metastases. Patients with metasta-
ses show significantly higher OPN and 
MIA levels than those without metastat -
 ic disease (p  ! 0.001, Mann-Whitney U 
test). 
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noma  [12, 13] . Increased OPN plasma levels have recent-
ly also been described in patients with metastatic uveal 
melanoma  [9, 10, 17] .
 The present study was undertaken to compare plasma 
levels of MIA and OPN in patients with and without me-
tastases from uveal melanoma and to assess a possible 
correlation between tumor height and MIA or OPN plas-
ma levels in patients without clinically detectable metas-
tases.
 We found a significant difference between plasma lev-
els in patients with and without clinically detectable me-
tastases for both markers. As 1 patient in our study group 
developed metastases during the observation period, we 
were able to observe a marked increase for both MIA and 
OPN plasma levels along with the generalization of the 
tumor. This indicates that, in addition to the registration 
of single values of OPN or MIA plasma levels, the devel-
opment or deviation from individual baseline values of 
these plasma levels over time should be taken into ac-
count  [6, 7, 19] .
 In the group of patients without clinically detectable 
metastases there was no statistically significant differ-
ence between the plasma levels both of MIA and OPN in 
patients with small, medium-sized or large melanomas. 
This confirms our previous results  [6–8] and suggests 
that both markers are independent of tumor size. In all 
three groups the plasma levels of both markers were sta-
tistically similar to those in healthy control groups  [15] . 
As described for other tumor markers in medicine, these 
results suggest that OPN and MIA are not adequate to 
diagnose or stage a primary tumor.
 In order to evaluate the quality of a diagnostic test a 
receiver-operating-characteristic curve (ROC) would be 
of great value. In this analysis, the true-positive rate (sen-
sitivity) is plotted against the false-positive rate (100 – 
specificity) for different cutoff points. A test with perfect 
discrimination has an ROC plot that passes through the 
upper left corner (100% sensitivity, 100% specificity). 
Therefore the closer the ROC plot is to the upper left cor-
ner, the higher the overall accuracy of the test. Another 
parameter for the quality of a diagnostic test in this anal-
ysis is the area under the curve  [20] .
 Recently, ROC curves were published for OPN and 
MIA  [17] . Such an analysis must, however, be based on a 
larger amount of data: a minimum of 50 patients in each 
group should be included for a statistically relevant cal-
culation  [20] . We hope to give a valid calculation after 
inclusion of a larger number of patients into the current 
investigation.
 In summary, OPN as well as MIA represent useful and 
cheap markers for the detection of metastatic disease and 
for the monitoring of patients with primary uveal mela-
noma. A low sensitivity of liver function testing (60% for 
alkaline phosphates, 50% for AST and 40% for ALT)  [17] 
as well as of abdominal ultrasonography and chest radi-
ography  [5] has already been demonstrated in the litera-
ture. Barak et al.  [17]  were able to demonstrate a consid-
erably higher sensitivity and specificity of MIA and OPN, 
and that the combination of these two biomarkers was far 
superior to liver function testing. Therefore, it may be 
hypothesized that MIA and OPN could represent valu-
able tools even for the early detection of metastasis in 
these patients, if applied routinely.
 The combination of both markers might increase the 
reliability of early detection giving our patients a chance 
for early intervention and prolonged survival. In the clin-
ical practice, OPN and MIA plasma levels could be mea-
sured for instance 3–4 times per year instead of liver func-
tion testing. In case of abnormal levels, subsequent tests 
such as CT scan, MRI or biopsy could be performed.
 In addition, MIA and OPN could play an important 
role in the monitoring of new treatment options for met-
astatic uveal melanoma.
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